The CBSB holds viable cellular fractions, DNAs and material for extracting RNA and protein where possible from over 2500 patients with myeloproliferative neoplasms, 3000 with myelodysplastic syndromes, over 250 with chronic lymphoproliferative disorders, as well as myelomas, acute leukaemias and a number of rare haematological malignancies.
Patients are mainly recruited from Cambridge University Hospitals NHS Trust, but we also have approval to recruit patients from a number of other specialist centres in the UK, and abroad. We prioritise the isolation, where possible, of high quality tumour and constitutional material for both nucleic acid based high throughput technologies and also cellular assays.
We also hold follow up samples on patients whose disease has progressed or relapsed. In addition to this work, we are also the research sample repository for an on-going clinical trial MAJIC, and PT1 which has now closed.